HC Wainwright restated their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO – Free Report) in a report issued on Tuesday, Benzinga reports. HC Wainwright currently has a $50.00 price target on the biopharmaceutical company’s stock. HALO has been the topic of a number of other reports. The Goldman Sachs Group dropped their price objective […]